The late-stage failure of Acelyrin, Inc.’s anti-IL-17 protein izokibep in hidradenitis suppurativa (HS) this month knocked the company badly, wiping 60% off its value (Also see "Acelyrin Goes From Float To Sink" - Scrip, 12 September, 2023.). Undaunted, Acelyrin is continuing with another Phase III trial.
The Runners And Riders In Hidradenitis Suppurativa
Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.
